Joel Solis

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez et al. · JAMA · 2022 · 294 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +12

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

Liam G. Heaney, John Busby, Catherine E. Hanratty et al. · The Lancet Respiratory Medicine · 2020 · 137 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez et al. · medRxiv · 2021 · 53 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16